USPTO serial 77858442
BTG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 12, 2010
- Examiner
- FRYE, KIMBERLY
- Law office
- TMO LAW OFFICE 113
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with BTG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, GB
London, GB
London, GB
PROTHERICS MEDICINES DEVELOPMENT LIMITED
London, GB
Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan A. Hyman
Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicine, namely, adjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease ] | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical and medicinal preparations and substances namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosis, [ inflammation, autoimmune disease and sleep disorders; dietetic foods adapted for medical use; ] vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposes, namely, for the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; [ pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of pain, including headache and migraine; ] pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdose, particularly overdose with methotrexate; [ pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; ] diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro | ACTIVE | — |
| 010 | Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose | ACTIVE | — |
| 042 | [ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named BTG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 14, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 13, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 12, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 12, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 12, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 12, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 12, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 30, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 24, 2021 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jun 24, 2021 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jun 24, 2021 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jun 22, 2021 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jun 9, 2021 | PR89 | POST REGISTRATION ACTION MAILED - SEC. 8 & 9 | — |
| Apr 14, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 9, 2021 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Aug 29, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 29, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 29, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 29, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 29, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 12, 2019 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 21, 2017 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Apr 21, 2017 | 8.PR | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | — |
| Apr 21, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 5, 2017 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Apr 5, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 12, 2015 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 15, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 15, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 14, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 6, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 12, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 27, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 27, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 22, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 21, 2010 | ALIE | ASSIGNED TO LIE | — |
| Jun 4, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 28, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 28, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2010 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 26, 2010 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 26, 2010 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 7, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 7, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2010 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Apr 21, 2010 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 21, 2010 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 21, 2010 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 31, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 31, 2009 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Oct 30, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 30, 2009 | NWAP | NEW APPLICATION ENTERED | — |